These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 39096891)
1. Anti-tumor effect of antibody-drug conjugate targeting cell adhesion molecule 1 on GIST cells representing small intestinal GIST. Yoshida M; Yuan J; Kihara T; Kimura N; Yamasaki T; Ohkouchi M; Hashikura Y; Isozaki K; Hagiyama M; Ito A; Hirota S Exp Mol Pathol; 2024 Oct; 139():104922. PubMed ID: 39096891 [TBL] [Abstract][Full Text] [Related]
2. Differential Expression of Yuan J; Kihara T; Kimura N; Hashikura Y; Ohkouchi M; Isozaki K; Takahashi T; Nishida T; Ito A; Hirota S Pathol Oncol Res; 2021; 27():602008. PubMed ID: 34257559 [TBL] [Abstract][Full Text] [Related]
3. Yuan J; Kihara T; Kimura N; Yamasaki T; Yoshida M; Isozaki K; Ito A; Hirota S Oncol Lett; 2022 Mar; 23(3):86. PubMed ID: 35126728 [TBL] [Abstract][Full Text] [Related]
4. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo. Boichuk S; Galembikova A; Dunaev P; Micheeva E; Novikova M; Khromova N; Kopnin P Anticancer Drugs; 2019 Jun; 30(5):475-484. PubMed ID: 30986804 [TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403 [TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases. Miettinen M; Sobin LH; Lasota J Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146 [TBL] [Abstract][Full Text] [Related]
7. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822 [TBL] [Abstract][Full Text] [Related]
8. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors. Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226 [TBL] [Abstract][Full Text] [Related]
9. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595 [TBL] [Abstract][Full Text] [Related]
10. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561 [TBL] [Abstract][Full Text] [Related]
11. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709 [TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumor: an ultrastructural investigation on regional differences with considerations on their histogenesis. Min KW Ultrastruct Pathol; 2010 May; 34(3):174-88. PubMed ID: 20455665 [TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib. Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287 [TBL] [Abstract][Full Text] [Related]
15. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086 [TBL] [Abstract][Full Text] [Related]
16. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202 [TBL] [Abstract][Full Text] [Related]
17. A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors. Fujimoto S; Muguruma N; Okamoto K; Kurihara T; Sato Y; Miyamoto Y; Kitamura S; Miyamoto H; Taguchi T; Tsuneyama K; Takayama T Theranostics; 2018; 8(9):2313-2328. PubMed ID: 29721082 [TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors. Wang S; Wang C; Wang X; Wang X; Huang L; Kuai J; Wei W; Lu X; Yan S Cancer Chemother Pharmacol; 2021 Nov; 88(5):795-804. PubMed ID: 34309733 [TBL] [Abstract][Full Text] [Related]